2:35
ICML 2017 | CLL update from ICML17: Current treatment and future directions for patients
Barbara Eichhorst
3:14
ESH 2017 | Resistance mechanisms to FLT3 inhibitors in AML
Katherine Smith
2:51
EHA 2017 | Two important therapies for ALL
Dieter Hoelzer
1:47
iwNHL 2016 | The potential clinical implications of targeted therapies for DLBCL and why the situation is complex
Clemens Schmitt
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals